Bristol Advisors’s AstraZeneca AZN Stock Holding History

Bristol Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-4,100	Closed	-$311K	–	34
2018 Q4	$311K	Hold	4,100	–	–	0.37%	37
2018 Q3	$324K	Buy	+4,100	New	+$310K	0.54%	28
2017 Q3	–	Sell	-8,300	Closed	-$566K	–	66
2017 Q2	$566K	Hold	8,300	–	–	0.38%	22
2017 Q1	$517K	Sell	8,300 -3,150	-28%	-$183K	0.59%	21
2016 Q4	$626K	Buy	+11,450	New	+$650K	0.63%	30

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bristol Advisors's AZN Position: Q1 2019 in Review

Bristol Advisors sold out of AstraZeneca (AZN) in Q1 2019, closing a stake of 4,100 shares — an estimated $311K sold.

Bristol Advisors first reported a position in AZN in Q4 2016 and held it in 5 quarters. The position peaked at $626K in Q4 2016. 559 funds tracked by Wall St. Rank hold AZN as of Q1 2019.

Bristol Advisors reported no remaining AstraZeneca position as of Q1 2019 after selling out during the quarter.
Bristol Advisors sold 4,100 AstraZeneca shares in Q1 2019, an estimated $311K.
Bristol Advisors first reported a position in AstraZeneca in Q4 2016 and held it in 5 quarters.
Bristol Advisors's AstraZeneca position peaked at $626K in Q4 2016.
559 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2019.

Based on Bristol Advisors's 13F filing for Q1 2019, filed 29 Apr 2019.